Liminatus Pharma, Inc. (LIMNW) stock
LIMNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMN
$0.04+0.00 (0.00%)
Close on Oct 30, 2026Market cap $189.39MP/E –Yield –
Liminatus Pharma total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Liminatus Pharma's total debt was $1.44M at Jun 30, 2026. For fiscal 2025 it was $1.44M, down 92.8% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44M | -92.8% |
| FY2024 | Dec 31, 2024 | $19.97M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.44M | 0.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.44M | -92.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.44M | – |
| Q3 FY2025 | Sep 30, 2025 | $1.44M | – |
| Q2 FY2025 | Jun 30, 2025 | $1.44M | – |
| Q4 FY2024 | Dec 31, 2024 | $19.97M | – |